08158 CRMI
- 0.285
- +0.015+5.56%
CRMI News
China Regenerative Medicine (08158.HK): Shareholders' share loss of approximately HK$108 million in 2023
On April 2, China Regenerative Medicine (08158.HK) announced that for the year ended December 31, 2023, revenue was approximately HK$69.49 million, an increase of 67.29% over the previous year; gross profit decreased by 48.37% from the previous year to approximately HK$19.42 million; the company's equity holders should account for the current year's loss of approximately HK$108 million (2022: profit of HK$4.56 million), with a basic loss of HK$37.60 per share.
CRMI: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023
Little Excitement Around China Regenerative Medicine International Limited's (HKG:8158) Revenues As Shares Take 25% Pounding
China Regenerative Medicine International Limited (HKG:8158) shares have had a horrible month, losing 25% after a relatively good period beforehand. For any long-term shareholders, the last month e
China Regenerative Medicine appoints Zhongzheng Tianheng as new auditor
China Regenerative Medicine (08158) issued an announcement. On January 25, 2024, Changying (Hong Kong) Certified Public Accountants Limited (Changying) submitted a letter of resignation to the board of directors to resign as the company's auditor, with immediate effect. On January 25, 2024, the board of directors delivered a notice to Changying, stating that after considering the company's cost-benefit factors and the company's failure to reach an agreement with Changying on the audit costs of the Group's comprehensive financial statements (annual review) for the year ended December 31, 2023, the board of directors resolved to recommend that Chang Ying resign as the company's auditor in order to hire another auditor to complete the annual review
China Regenerative Medicine (08158.HK) appoints Zhongzheng Tianheng as new auditor
Gelonghui, January 25 | China Regenerative Medicine (08158.HK) announced that Changying (Hong Kong) Certified Public Accountants Limited (“Changying”) submitted a letter of resignation to the board of directors to resign as the company's auditor with immediate effect. Following the recommendation of the Audit Committee, it has decided to appoint Zhongzheng Tianheng Certified Public Accountants Co., Ltd. (“Zhongzheng Tianheng”) as the company's new auditor.
China Regenerative Medicine (08158) affiliate plans to inject 10.25 million yuan into Changzhou Pomei Biotechnology
Zhitong Finance App News, China Regenerative Medicine (08158) announced that on December 29, 2023 (after the transaction period), China Regenerative Health, Changzhou Starry Sky, and the target company Changzhou Bomei Biotechnology Co., Ltd. signed a capital increase and subscription agreement. According to this, China Regenerative Health must inject RMB 10.25 million into the target company in cash, of which RMB 250,000 will be injected to increase the target company's registered capital, while RMB 10 million will be injected into its capital reserve. Upon completion, the target company will hold approximately 33.3% of China Regenerative Health's equity and Changzhou Star
China Regenerative Medicine International Limited (HKG:8158) Held Back By Insufficient Growth Even After Shares Climb 42%
China Regenerative Medicine International Limited (HKG:8158) shareholders are no doubt pleased to see that the share price has bounced 42% in the last month, although it is still struggling to make up
CRMI: THIRD QUARTERLY RESULTS ANNOUNCEMENT FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2023
CRMI: Third Quarterly Report 2023
China Regenerative Medicine (08158) released its first three quarter results, net profit of HK$6.677 million, down 36.7% year on year
China Regenerative Medicine (08158) announced the results for the nine months ended September 30, 2023, with revenue of 112 million...
CRMI: THIRD QUARTERLY RESULTS ANNOUNCEMENT FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2023
China Regenerative Medicine cut 2,569 million shares due to share mergers on a “10 to 1” basis
China Regenerative Medicine (08158) announced a reduction of 2,569 million shares due to a share merger on a “10 to 1” basis.
China Regenerative Medicine announced that trading of consolidated shares will begin on September 6
China Regenerative Medicine (08158) announced that after approval by the GEM Listing Committee for the listing and trading of the consolidated shares, trading of the consolidated shares will begin at 9:00 a.m. on September 6, 2023 (Wednesday). The adjustments to share options that have not yet been exercised will take effect on September 6, 2023 (Wednesday).
China Regenerative Medicine announced interim results, net profit of HK$127.62 million, up 4.74 times year-on-year
China Regenerative Medicine (08158) announced its 2023 interim results, with earnings of approximately HK$100 million, up 16.04% year on year; net profit of HK$127.62 million, up 4.74 times year on year; and profit of HK0.447 cents per share.
China Regenerative Medicine (08158) announced interim results; net profit of HK$127.62 million increased 4.74 times year-on-year
According to the Zhitong Finance App, China Regenerative Medicine (08158) announced its 2023 interim results, with revenue of about HK$100 million, an increase of 16.04%; net profit of HK$12.762 million, an increase of 4.74 times over the previous year; profit of HK0.447 cents per share.
CRMI: Interim Report 2023
CRMI: INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2023
CRMI To Carry Out 1-for-10 Reverse Stock Split On September 6th, 2023
August 5th - $CRMI(08158.HK)$ is about to implement a 1-for-10 reverse stock split of shares. The shares will begin trading on a split-adjusted basis from September 6th, 2023.$CRMI(08158.HK)$ slipped
CRMI: NOTICE OF BOARD MEETING
China Regenerative Medicine (08158) plans to restructure its share capital
According to the Zhitong Finance App, China Regenerative Medicine (08158) issued an announcement. The board of directors proposed implementing a share merger. The benchmark is to merge every 10 issued and unissued existing shares into 1 consolidated share. A share merger must wait (including) the shareholders to approve an ordinary resolution at the Extraordinary General Meeting of Shareholders before being effective. The Board of Directors recommended implementing a reduction in share capital immediately following the entry into force of the share merger. The cancellation of any fragmented consolidated shares of the company's issued share capital resulting from the share merger and the company's issued share capital will be reduced through cancellation of the full paid share capital (up to the cancellation of HK$1.80 for each consolidated share issued at the time).
Analysis
Price Target
No Data
